Billy's questions to Vir Biotechnology Inc (VIR) leadership • Q4 2024
Question
Billy, on behalf of JPMorgan, asked if Vir plans to pursue an every-three-week dosing schedule for its EGFR T-cell engager, VIR-5525, similar to its other two T-cell engager programs.
Answer
CEO Dr. Marianne De Backer confirmed that Vir is exploring both weekly and every-three-week dosing for the HER2 and PSMA programs and plans to do the same for the EGFR program. She noted that the pharmacokinetic half-life data from the existing clinical programs is encouraging for less frequent dosing schedules.